Global Macular Degeneration Drug Pipeline Market Insights, Forecast to 2028

Table Of Contents

1 Report Business Overview

1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Gene therapy 1.2.3 Small molecules 1.2.4 Stem cell therapy 1.2.5 Gene therapies 1.3 Market by Application 1.3.1 Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Hospital 1.3.3 Research Institute 1.3.4 Commercial 1.3.5 Other 1.4 Study Objectives 1.5 Years Considered2 Global Growth Trends 2.1 Global Macular Degeneration Drug Pipeline Market Perspective (2017-2028) 2.2 Macular Degeneration Drug Pipeline Growth Trends by Region 2.2.1 Macular Degeneration Drug Pipeline Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Macular Degeneration Drug Pipeline Historic Market Size by Region (2017-2022) 2.2.3 Macular Degeneration Drug Pipeline Forecasted Market Size by Region (2023-2028) 2.3 Macular Degeneration Drug Pipeline Market Dynamics 2.3.1 Macular Degeneration Drug Pipeline Industry Trends 2.3.2 Macular Degeneration Drug Pipeline Market Drivers 2.3.3 Macular Degeneration Drug Pipeline Market Challenges 2.3.4 Macular Degeneration Drug Pipeline Market Restraints3 Competition Landscape by Key Players 3.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue 3.1.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue (2017-2022) 3.1.2 Global Macular Degeneration Drug Pipeline Revenue Market Share by Players (2017-2022) 3.2 Global Macular Degeneration Drug Pipeline Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Macular Degeneration Drug Pipeline Revenue 3.4 Global Macular Degeneration Drug Pipeline Market Concentration Ratio 3.4.1 Global Macular Degeneration Drug Pipeline Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration Drug Pipeline Revenue in 2021 3.5 Macular Degeneration Drug Pipeline Key Players Head office and Area Served 3.6 Key Players Macular Degeneration Drug Pipeline Product Solution and Service 3.7 Date of Enter into Macular Degeneration Drug Pipeline Market 3.8 Mergers & Acquisitions, Expansion Plans4 Macular Degeneration Drug Pipeline Breakdown Data by Type 4.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Type (2017-2022) 4.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2023-2028)5 Macular Degeneration Drug Pipeline Breakdown Data by Application 5.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Application (2017-2022) 5.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2023-2028)6 North America 6.1 North America Macular Degeneration Drug Pipeline Market Size (2017-2028) 6.2 North America Macular Degeneration Drug Pipeline Market Size by Type 6.2.1 North America Macular Degeneration Drug Pipeline Market Size by Type (2017-2022) 6.2.2 North America Macular Degeneration Drug Pipeline Market Size by Type (2023-2028) 6.2.3 North America Macular Degeneration Drug Pipeline Market Share by Type (2017-2028) 6.3 North America Macular Degeneration Drug Pipeline Market Size by Application 6.3.1 North America Macular Degeneration Drug Pipeline Market Size by Application (2017-2022) 6.3.2 North America Macular Degeneration Drug Pipeline Market Size by Application (2023-2028) 6.3.3 North America Macular Degeneration Drug Pipeline Market Share by Application (2017-2028) 6.4 North America Macular Degeneration Drug Pipeline Market Size by Country 6.4.1 North America Macular Degeneration Drug Pipeline Market Size by Country (2017-2022) 6.4.2 North America Macular Degeneration Drug Pipeline Market Size by Country (2023-2028) 6.4.3 United States 6.4.4 Canada7 Europe 7.1 Europe Macular Degeneration Drug Pipeline Market Size (2017-2028) 7.2 Europe Macular Degeneration Drug Pipeline Market Size by Type 7.2.1 Europe Macular Degeneration Drug Pipeline Market Size by Type (2017-2022) 7.2.2 Europe Macular Degeneration Drug Pipeline Market Size by Type (2023-2028) 7.2.3 Europe Macular Degeneration Drug Pipeline Market Share by Type (2017-2028) 7.3 Europe Macular Degeneration Drug Pipeline Market Size by Application 7.3.1 Europe Macular Degeneration Drug Pipeline Market Size by Application (2017-2022) 7.3.2 Europe Macular Degeneration Drug Pipeline Market Size by Application (2023-2028) 7.3.3 Europe Macular Degeneration Drug Pipeline Market Share by Application (2017-2028) 7.4 Europe Macular Degeneration Drug Pipeline Market Size by Country 7.4.1 Europe Macular Degeneration Drug Pipeline Market Size by Country (2017-2022) 7.4.2 Europe Macular Degeneration Drug Pipeline Market Size by Country (2023-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries8 Asia-Pacific 8.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size (2017-2028) 8.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type 8.2.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2017-2022) 8.2.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2023-2028) 8.2.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Share by Type (2017-2028) 8.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application 8.3.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2017-2022) 8.3.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2023-2028) 8.3.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Share by Application (2017-2028) 8.4 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region 8.4.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2017-2022) 8.4.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2023-2028) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Macular Degeneration Drug Pipeline Market Size (2017-2028) 9.2 Latin America Macular Degeneration Drug Pipeline Market Size by Type 9.2.1 Latin America Macular Degeneration Drug Pipeline Market Size by Type (2017-2022) 9.2.2 Latin America Macular Degeneration Drug Pipeline Market Size by Type (2023-2028) 9.2.3 Latin America Macular Degeneration Drug Pipeline Market Share by Type (2017-2028) 9.3 Latin America Macular Degeneration Drug Pipeline Market Size by Application 9.3.1 Latin America Macular Degeneration Drug Pipeline Market Size by Application (2017-2022) 9.3.2 Latin America Macular Degeneration Drug Pipeline Market Size by Application (2023-2028) 9.3.3 Latin America Macular Degeneration Drug Pipeline Market Share by Application (2017-2028) 9.4 Latin America Macular Degeneration Drug Pipeline Market Size by Country 9.4.1 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2017-2022) 9.4.2 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2023-2028) 9.4.3 Mexico 9.4.4 Brazil10 Middle East & Africa 10.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size (2017-2028) 10.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type 10.2.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2017-2022) 10.2.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2023-2028) 10.2.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Share by Type (2017-2028) 10.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application 10.3.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2017-2022) 10.3.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2023-2028) 10.3.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Share by Application (2017-2028) 10.4 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country 10.4.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2017-2022) 10.4.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2023-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE11 Key Players Profiles 11.1 Amgen 11.1.1 Amgen Company Details 11.1.2 Amgen Business Overview 11.1.3 Amgen Macular Degeneration Drug Pipeline Introduction 11.1.4 Amgen Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.1.5 Amgen Recent Developments 11.2 Roche 11.2.1 Roche Company Details 11.2.2 Roche Business Overview 11.2.3 Roche Macular Degeneration Drug Pipeline Introduction 11.2.4 Roche Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.2.5 Roche Recent Developments 11.3 Adverum Biotechnologies 11.3.1 Adverum Biotechnologies Company Details 11.3.2 Adverum Biotechnologies Business Overview 11.3.3 Adverum Biotechnologies Macular Degeneration Drug Pipeline Introduction 11.3.4 Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.3.5 Adverum Biotechnologies Recent Developments 11.4 AsclepiX Therapeutics 11.4.1 AsclepiX Therapeutics Company Details 11.4.2 AsclepiX Therapeutics Business Overview 11.4.3 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Introduction 11.4.4 AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.4.5 AsclepiX Therapeutics Recent Developments 11.5 Bioeq AG 11.5.1 Bioeq AG Company Details 11.5.2 Bioeq AG Business Overview 11.5.3 Bioeq AG Macular Degeneration Drug Pipeline Introduction 11.5.4 Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.5.5 Bioeq AG Recent Developments 11.6 Sinocelltech 11.6.1 Sinocelltech Company Details 11.6.2 Sinocelltech Business Overview 11.6.3 Sinocelltech Macular Degeneration Drug Pipeline Introduction 11.6.4 Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.6.5 Sinocelltech Recent Developments 11.7 RemeGen 11.7.1 RemeGen Company Details 11.7.2 RemeGen Business Overview 11.7.3 RemeGen Macular Degeneration Drug Pipeline Introduction 11.7.4 RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.7.5 RemeGen Recent Developments 11.8 Grifols, S.A. 11.8.1 Grifols, S.A. Company Details 11.8.2 Grifols, S.A. Business Overview 11.8.3 Grifols, S.A. Macular Degeneration Drug Pipeline Introduction 11.8.4 Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.8.5 Grifols, S.A. Recent Developments 11.9 Kyowa Kirin 11.9.1 Kyowa Kirin Company Details 11.9.2 Kyowa Kirin Business Overview 11.9.3 Kyowa Kirin Macular Degeneration Drug Pipeline Introduction 11.9.4 Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.9.5 Kyowa Kirin Recent Developments 11.10 EyePoint Pharmaceutical 11.10.1 EyePoint Pharmaceutical Company Details 11.10.2 EyePoint Pharmaceutical Business Overview 11.10.3 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Introduction 11.10.4 EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.10.5 EyePoint Pharmaceutical Recent Developments 11.11 IVERIC Bio 11.11.1 IVERIC Bio Company Details 11.11.2 IVERIC Bio Business Overview 11.11.3 IVERIC Bio Macular Degeneration Drug Pipeline Introduction 11.11.4 IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.11.5 IVERIC Bio Recent Developments 11.12 Kodiak Sciences 11.12.1 Kodiak Sciences Company Details 11.12.2 Kodiak Sciences Business Overview 11.12.3 Kodiak Sciences Macular Degeneration Drug Pipeline Introduction 11.12.4 Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.12.5 Kodiak Sciences Recent Developments 11.13 Ribomic 11.13.1 Ribomic Company Details 11.13.2 Ribomic Business Overview 11.13.3 Ribomic Macular Degeneration Drug Pipeline Introduction 11.13.4 Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.13.5 Ribomic Recent Developments 11.14 Lineage Cell Therapeutics 11.14.1 Lineage Cell Therapeutics Company Details 11.14.2 Lineage Cell Therapeutics Business Overview 11.14.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Introduction 11.14.4 Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.14.5 Lineage Cell Therapeutics Recent Developments 11.15 Graybug Vision 11.15.1 Graybug Vision Company Details 11.15.2 Graybug Vision Business Overview 11.15.3 Graybug Vision Macular Degeneration Drug Pipeline Introduction 11.15.4 Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.15.5 Graybug Vision Recent Developments 11.16 CHABiotech 11.16.1 CHABiotech Company Details 11.16.2 CHABiotech Business Overview 11.16.3 CHABiotech Macular Degeneration Drug Pipeline Introduction 11.16.4 CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.16.5 CHABiotech Recent Developments 11.17 Shanghai Henlius Biotech 11.17.1 Shanghai Henlius Biotech Company Details 11.17.2 Shanghai Henlius Biotech Business Overview 11.17.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Introduction 11.17.4 Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.17.5 Shanghai Henlius Biotech Recent Developments 11.18 Bio-Thera Solutions 11.18.1 Bio-Thera Solutions Company Details 11.18.2 Bio-Thera Solutions Business Overview 11.18.3 Bio-Thera Solutions Macular Degeneration Drug Pipeline Introduction 11.18.4 Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.18.5 Bio-Thera Solutions Recent Developments 11.19 Alteogen 11.19.1 Alteogen Company Details 11.19.2 Alteogen Business Overview 11.19.3 Alteogen Macular Degeneration Drug Pipeline Introduction 11.19.4 Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.19.5 Alteogen Recent Developments 11.20 Outlook Therapeutics 11.20.1 Outlook Therapeutics Company Details 11.20.2 Outlook Therapeutics Business Overview 11.20.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Introduction 11.20.4 Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2017-2022) 11.20.5 Outlook Therapeutics Recent Developments12 Analyst's Viewpoints/Conclusions13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer